Volume 25, Number 7—July 2019
Dispatch
Microbiome and Antimicrobial Resistance Gene Dynamics in International Travelers
Table 1
Traveler | Destination | Duration, d | Diarrhea | Pretravel | Posttravel | 30 d posttravel | 6 mo posttravel |
---|---|---|---|---|---|---|---|
T1 | Nepal | 30 | N | – | AmpC | OXA-209 | OXA-209 |
T2 | Nepal | 30 | N | – | AmpC, CTX-M1 | AmpC | – |
T3 | Nepal | 30 | N | OXA-209 | AmpC, CTX-M1, OXA-209 | OXA-209 | OXA-209 |
T4 | Nepal | 16 | N | – | AmpC | – | NR |
T5 | Nepal | 30 | Y | – | AmpC, SHV-12 | AmpC | AmpC, CTX-M-1 |
T6 | Nepal | 15 | Y | – | AmpC, CTX-M-1 | – | – |
T7 | Nepal | 18 | N | – | AmpC, CTX-M-1 | NR | NR |
T8 | Uganda | 14 | N | – | – (AmpC)† | – | – |
T9 | Nigeria | 60 | Y | – | AmpC | – | – |
T10 | Nepal | 30 | Y | – | AmpC, CTX-M-1 | – | NR |
*Participants submitted samples pretravel (within 1 week before departure), posttravel (within 1 week after return), 30 days posttravel, and 6 months posttravel. ESBL, extended-spectrum β-lactamase; N, no; NR, no sample received; Y, yes; –, ESBL-negative by culture.
†T8 was the only participant who was phenotypically ESBL-negative after travel.
1These authors contributed equally to this article.
Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.